Mineralys Therapeutics (MLYS) vs OPKO Health (OPK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
OPKO Health (OPK) has outperformed Mineralys Therapeutics (MLYS) over the past year, gaining 18.9% versus a loss of 67.4%. Mineralys Therapeutics is the larger company by market cap ($1.21 billion vs $1.17 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MLYS | OPK |
|---|---|---|
| Share price | $13.66 | $1.57 |
| Market cap | $1.21B | $1.17B |
| 1-day change | -3.53% | -2.48% |
| YTD return | -62.36% | +24.60% |
| 1-year return | -67.38% | +18.94% |
| 5-year return | — | -61.99% |
| EPS (TTM) | $-4.30 | $-0.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $606.88M |
| Revenue growth (YoY) | — | -14.90% |
| Net income (latest FY) | $-154.65M | $-225.68M |
| Gross margin | — | 33.93% |
| Operating margin | — | -19.35% |
| Net margin | — | -37.19% |
| 52-week high | $44.13 | $1.86 |
| 52-week low | $13.57 | $0.98 |
| Distance from 52-week high | -69.05% | -15.59% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +218.89% | +164.33% |
| Average volume | 1.55M | 3.83M |
| Shares outstanding | 88.56M | 742.51M |
| Employees | 76 | 2,275 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OPK has outperformed MLYS by 86.3 percentage points over the past year.
About Mineralys Therapeutics
MLYS stock →Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea.
Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees
About OPKO Health
OPK stock →OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,275 employees
MLYS vs OPK FAQ
Which is bigger, Mineralys Therapeutics or OPKO Health?
Mineralys Therapeutics (MLYS) is larger, with a market capitalization of $1.21B compared with $1.17B for OPKO Health (OPK).
Which stock has performed better over the past year, MLYS or OPK?
OPK returned +18.94% over the past 12 months, compared with -67.38% for MLYS (price return, excluding dividends). Past performance does not predict future results.
Are Mineralys Therapeutics and OPKO Health in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.